Rocket Pharmaceuticals Investor Presentation — February 2022

Document content

SEEKING GENE THERAPY CURES2DISCLAIMER

Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations

regarding its guidance for 2022 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket maydevelop, to treat

Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD),and Danon Disease, and the safety, effectiveness and

timing of related pre-clinical studies and clinical trials and related data readouts, may constitute forward-looking statements for the purposes of the

safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks,

uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words suchas "believe,"

"expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the

negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot

guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various

important factors, including, without limitation, Rocket's ability to monitor the impact of COVID-19 on its business operations and take steps to

ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, our

expectations regarding when clinical trial sites will resume normal business operations, our expectations regarding the delays and impact of COVID-

19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated

trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product

candidates, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the

outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "RiskFactors" in Rocket’s

Annual Report on Form 10-K for the year ended December 31, 2021, filed February 28, 2022 with theSEC and subsequent filings with the SEC

including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such